Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine hydroxymethyltransferase (SHMT) and Cystathionine β-synthase (CBS) are two distinct pyridoxal 5'-phosphate (PLP)-dependent enzymes that play pivotal roles in cellular metabolism. SHMT, particularly the mitochondrial isoform SHMT2, is a key enzyme in the one-carbon metabolism pathway, facilitating the conversion of serine to glycine and providing one-carbon units necessary for DNA synthesis and repair (UniProt P34897). Cystathionine β-synthase (CBS) is the rate-limiting enzyme in the transsulfuration pathway, converting homocysteine and serine into cystathionine, which is a precursor for cysteine and the gasotransmitter hydrogen sulfide (H2S) (UniProt P35520). Deficiencies in CBS lead to homocystinuria, a serious metabolic disorder, while its overexpression in certain cancers contributes to tumor growth via H2S signaling (PubMed: 25653181). Although both enzymes utilize serine as a substrate and are PLP-dependent, they are separate proteins encoded by different genes and are not typically considered a single therapeutic target. Experimental inhibitors like SHIN1 and SHIN2 target SHMT to disrupt cancer cell proliferation, whereas compounds like aminooxyacetic acid are used in research to inhibit CBS activity (PubMed: 28604678, 23690555). Targeting these enzymes offers therapeutic potential in oncology and metabolic diseases, though selectivity remains a challenge due to their shared reliance on the PLP cofactor.
Inhibition of enzymatic activity to disrupt one-carbon metabolism or hydrogen sulfide production.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine hydroxymethyltransferase (SHMT) and Cystathionine β-synthase (CBS) (SHMT/CBS).